Australien - Englisch - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - bovine lactoferrin,hedera helix -

Kanada - Englisch - Health Canada

bayer healthcare llc - antihemophilic factor (recombinant) - powder for solution - 250unit - antihemophilic factor (recombinant) 250unit - hemostatics

Kanada - Englisch - Health Canada

bayer healthcare llc - antihemophilic factor (recombinant) - powder for solution - 500unit - antihemophilic factor (recombinant) 500unit - hemostatics

Kanada - Englisch - Health Canada

bayer healthcare llc - antihemophilic factor (recombinant) - powder for solution - 1000unit - antihemophilic factor (recombinant) 1000unit - hemostatics

Kanada - Englisch - Health Canada

bayer healthcare llc - antihemophilic factor (recombinant) - powder for solution - 2000unit - antihemophilic factor (recombinant) 2000unit - hemostatics

Kanada - Englisch - Health Canada

pharmaceutical partners of canada inc - epirubicin hydrochloride - solution - 2mg - epirubicin hydrochloride 2mg - antineoplastic agents

Kanada - Englisch - Health Canada

bayer healthcare llc - antihemophilic factor (recombinant) - powder for solution - 3000unit - antihemophilic factor (recombinant) 3000unit - hemostatics

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

helix pharmaceuticals pty ltd - dasatinib, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; ethylcellulose; triethyl citrate; colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; hyprolose; titanium dioxide; hypromellose - dasatinib viatris is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

helix pharmaceuticals pty ltd - dasatinib, quantity: 70 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; titanium dioxide; triethyl citrate; croscarmellose sodium; ethylcellulose; lactose monohydrate; hypromellose; hyprolose; colloidal anhydrous silica - dasatinib viatris is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

helix pharmaceuticals pty ltd - dasatinib, quantity: 100 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate; hyprolose; ethylcellulose; hypromellose; magnesium stearate; triethyl citrate; titanium dioxide; microcrystalline cellulose - dasatinib viatris is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy